Skip to main content
 

Interleukin 37 negatively associates with coronary plaque burden in psoriasis

Friday, September 15, 2017 — Poster Session IV

1:00 p.m. – 2:30 p.m.
FAES Terrace
NHLBI
IMMUNO-6

Authors

  • CL Harrington
  • AK Dey
  • Y Baumer
  • AD Belur
  • YA Elnbawi
  • A Goyal
  • Q Ng
  • A Sajja
  • GE Sanda
  • AV Sorokin
  • HL Teague
  • NJ Varghese
  • MP Playford
  • NN Mehta

Abstract

Inflammation is associated with initiation and progression of atherosclerosis. Numerous studies have shown that psoriasis (PSO), a chronic inflammatory condition, is linked to increased risk for cardiovascular disease (CVD) development. Interleukin (IL)- 37 is a newly discovered anti-inflammatory member of the IL-1 cytokine family and has been shown to be regulated in inflammatory disease. Whether IL-37 is associated with subclinical CVD in PSO is not known. We hypothesized that the plasma levels of IL-37 in a PSO cohort would negatively associate with coronary computed tomography angiography (CCTA)-derived coronary plaque burden, a reliable marker of subclinical atherosclerosis. A cohort of PSO subjects (n=66) underwent CCTA scans as part of a large observational study to assess coronary plaque burden and IL-37 plasma levels were measured by ELISA assay. PSO patients were middle aged with low Framingham risk. In an unadjusted multivariable regression, IL-37 strongly inversely associated with both total coronary burden (ß=-0.30, p

Category: Immunology